Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301532 · ClinicalTrials.gov registry record · Phase 2
Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D
A Phase 2 study of GLUT1DS1, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03301532 is a Phase 2 study of GLUT1DS1 that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03301532, a Phase 2 study of GLUT1DS1, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To explore triheptanoin (C7 oil) compatibility with the ketogenic diet by evaluating EEG, and seizure rate, glycemia and ketosis in proven G1D patients receiving a ketogenic diet.
Conditions Studied
Interventions
- DRUG Triheptanoin
Study Locations (1)
Texas
- UTexasSouthwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-06-05 |
| Est. Completion | 2022-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03301532
The ClinicalTrials.gov registry entry for NCT03301532 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GLUT1DS1 appearing as the primary indexed condition, and to 1 intervention - of which Triheptanoin is the first listed.
NCT03301532 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03301532 about?
NCT03301532 is a clinical study titled "Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D". To explore triheptanoin (C7 oil) compatibility with the ketogenic diet by evaluating EEG, and seizure rate, glycemia and ketosis in proven G1D patients receiving a ketogenic diet.
What is the current status of trial NCT03301532?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-06-05. Estimated completion is 2022-07-31.
What conditions does trial NCT03301532 study?
This clinical trial studies the following conditions: GLUT1DS1.
What interventions are being tested in trial NCT03301532?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT03301532?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03301532 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GLUT1DS1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.